I'm betting on a value trap.🤷🏼♂️ The share price has been moving downwards in a clear trend channel for 5 years (!!!).
You can hardly run down a staircase more elegantly.😅😂
It is exciting that analysts are still so bullish and see considerable upside.🫣
To be honest, I also think the margin profile is pretty thin for a global market leader whose main sales come from consumables.
Take a look at $MEDI and compare the margin profiles. Of course, it's an "apples and oranges" comparison due to the size, but: this is what market dominance looks like in the margin profile (from my point of view😉).
You can hardly run down a staircase more elegantly.😅😂
It is exciting that analysts are still so bullish and see considerable upside.🫣
To be honest, I also think the margin profile is pretty thin for a global market leader whose main sales come from consumables.
Take a look at $MEDI and compare the margin profiles. Of course, it's an "apples and oranges" comparison due to the size, but: this is what market dominance looks like in the margin profile (from my point of view😉).
•
11
•
1Settimana
@Get_Rich_or_Die_Tryin Thank you, you hit two very sore points.
On the chart: Absolutely right. The downward trend started at the extreme coronavirus peak (P/E ratio > 50) and is now being fueled by the China investment backlog.
On the margins: The comparison with $MEDI is understandable! Medistim operates in a highly profitable niche (cardiac surgery) with enormous pricing power. Sysmex is the mass market (routine blood counts) and often has to place expensive hardware at low prices in order to generate reagent sales at all. This naturally depresses the overall margin. I see Sysmex more as an anti-cyclical turnaround bet.
Thanks for the tip, I'll take a closer look at Medistim at the weekend. I hadn't heard of it before.
On the chart: Absolutely right. The downward trend started at the extreme coronavirus peak (P/E ratio > 50) and is now being fueled by the China investment backlog.
On the margins: The comparison with $MEDI is understandable! Medistim operates in a highly profitable niche (cardiac surgery) with enormous pricing power. Sysmex is the mass market (routine blood counts) and often has to place expensive hardware at low prices in order to generate reagent sales at all. This naturally depresses the overall margin. I see Sysmex more as an anti-cyclical turnaround bet.
Thanks for the tip, I'll take a closer look at Medistim at the weekend. I hadn't heard of it before.
•
11
•